<table id="table13" width="75%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 13         Amino Acid Substitutions in Viremic Subjects across HBV Trials of VIREAD</caption>
<col align="left" valign="top" width="28%"></col>
<col align="center" valign="middle" width="18%"></col>
<col align="center" valign="middle" width="18%"></col>
<col align="center" valign="middle" width="18%"></col>
<col align="center" valign="middle" width="18%"></col>
<thead>
<tr>
<th rowspan="2" stylecode="Rrule"></th>
<th colspan="3" stylecode="Rrule Botrule" valign="top">Compensated Liver Disease</th>
<th rowspan="2" valign="top">Decompensated Liver Disease  (N=39)
                  
    
     <footnote id="t13f4">Subjects with decompensated liver disease from Study 0108 (N=39) receiving up to 48 weeks of treatment with VIREAD.</footnote>
</th>
</tr>
<tr stylecode="Botrule">
<th align="center" stylecode="Rrule" valign="top">Nucleotide-Naïve      (N=417)
                  
    
     <footnote id="t13f1">Nucleotide-naïve subjects from Studies 0102 (N=246) and 0103 (N=171) receiving up to 240 weeks of treatment with VIREAD.</footnote>
</th>
<th stylecode="Rrule" valign="top">HEPSERA-Experienced (N=247)
                  
    
     <footnote id="t13f2">HEPSERA-experienced subjects from Studies 0102/0103 (N=195) and 0106 (N=52) receiving up to 192 weeks of treatment with VIREAD after switching to VIREAD from HEPSERA.  Study 0106, a randomized, double-blind, 168-week Phase 2 trial, has been completed.</footnote>
</th>
<th stylecode="Rrule" valign="top">Lamivudine- Resistant (N=136)
                  
    
     <footnote id="t13f3">Lamivudine-resistant subjects from Study 0121 (N=136) receiving up to 96 weeks of treatment with VIREAD after switching to VIREAD from lamivudine.</footnote>
</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Rrule">Viremic at Last Time Point on VIREAD</td>
<td stylecode="Rrule">35/417 (8%)</td>
<td stylecode="Rrule">34/247 (14%)</td>
<td stylecode="Rrule">9/136 (7%)</td>
<td>7/39 (18%)</td>
</tr>
<tr>
<td stylecode="Rrule">Treatment-Emergent Amino Acid Substitutions
                  
    
     <footnote id="t135">Denominator includes those subjects who were viremic at last time point on VIREAD monotherapy and had evaluable paired genotypic data.</footnote>
</td>
<td stylecode="Rrule">19
                  
    
     <footnote id="t13f6">Of the 19 subjects with treatment-emergent amino acid substitutions during Studies 0102 and 0103, 5 subjects had substitutions at conserved sites and 14 subjects had substitutions only at polymorphic sites, and 8 subjects had only transient substitutions that were not detected at the last time point on VIREAD.</footnote>/33 (58%)
                 
   
    </td>
<td stylecode="Rrule">10
                  
    
     <footnote id="t13f7">Of the 10 HEPSERA-experienced subjects with treatment-emergent amino acid substitutions, 2 subjects had substitutions at conserved sites and 8 had substitutions only at polymorphic sites.</footnote>/27 (37%)
                 
   
    </td>
<td stylecode="Rrule">6
                  
    
     <footnote id="t13f8">Of the 6 lamivudine-resistant subjects with treatment-emergent substitutions during Study 0121, 3 subjects had substitutions at conserved sites and 3 had substitutions only at polymorphic sites.</footnote>/8 (75%)
                 
   
    </td>
<td>3/5 (60%)</td>
</tr>
</tbody>
</table>